Chemodex

ONC212

CHF 0.00
Out of stock
NEW
 
More Information
Product Details
Synonyms TR-31; 7-Benzyl-4-(4-(trifluoromethyl)benzyl)-2,4,6,7,8,9-hexahydroimidazo[1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one; NSC-783745
Product Type Chemical
Properties
Formula C24H23F3N4O
MW 440.5
CAS 1807861-48-8
Source/Host Chemicals Synthetic
Purity Chemicals ≥98% (HPLC)
Appearance Solid.
Solubility Soluble in DMSO.
Declaration Manufactured by Chemodex.
Other Product Data

Click here for Original Manufacturer Product Datasheet
Our product description may differ slightly from the original manufacturers product datasheet.

InChi Key DFULPGUTXZTYKA-UHFFFAOYSA-N
Smiles O=C(N(CC1=CC=C(C(F)(F)F)C=C1)C2=NCCN23)C4=C3CCN(CC5=CC=CC=C5)C4
Shipping and Handling
Shipping AMBIENT
Short Term Storage +4°C
Long Term Storage -20°C
Handling Advice Protect from light and moisture.
Use/Stability Stable for at least 2 years after receipt when stored at -20°C.
Documents
Product Specification Sheet
Datasheet Download PDF
Description
ONC212 is a potent imipridone small-molecule (and fluorinated imipridone analog of ONC201) that acts as a dual agonist of the mitochondrial protease ClpP and the orphan GPCR GPR132, provoking mitochondrial dysfunction, integrated stress response, and apoptotic cell death, particularly in acute leukemia and solid tumor models. By targeting the mitochondrial protease ClpP, this engagement disrupts mitochondrial function, impairs oxidative phosphorylation and contributes to its anti-tumor activity across diverse preclinical cancer models. Acting as an agonist of the orphan G protein-coupled receptor GPR132, triggering downstream Gαq signaling and the integrated stress response, contributes to its pronounced anti-leukemic effects, particularly in acute myeloid leukemia models.
Product References
(1) J. Wagner, et al.; Cell Cycle 16, 1790 (2017) | (2) T. Nii, et al.; Leukemia. 33, 2805 (2019) | (3) S. Jacques, et al.; Genetics 214, 1103 (2020) | (4) E.R. Bonner, et al.; Neuro. Oncol. 23, 542 (2021) | (5) N. Fatima, et al.; E. J. Heam. 2, 81 (2021) | (6) I, Ferrarini, et al.; Mol. Cancer Ther. 20, 1572 (2021) | (7) V. Basu, et al.; Cell Commun. Signal 22, 441 (2024)
© 2017 Adipogen Life Sciences. Pictures: © 2012 Martin Oeggerli. All Rights Reserved.